Cancer Immunology Reserch

Cancer Immunol Res. 2026 Apr 27. doi: 10.1158/2326-6066.CIR-25-0982. Online ahead of print. ABSTRACT The combination of multikinase inhibitors with PD-1 blockade therapy has emerged as a promising strategy to overcome resistance to PD-1 blockade monotherapy across multiple cancer types, including gastric cancer (GC). Here, we report that the multikinase inhibitor lenvatinib selectively reduced the number … Read more

Cancer Immunol Res. 2026 Apr 27. doi: 10.1158/2326-6066.CIR-25-0529. Online ahead of print. ABSTRACT Engineered T cell therapies, such as chimeric antigen receptor (CAR) and T cell receptor (TCR)-based approaches, have transformed outcomes in hematological malignancies, yet their efficacy in solid tumors remains limited by tumor antigen escape, immunosuppressive microenvironments, and insufficient activation of CAR or … Read more

Cancer Immunol Res. 2026 Apr 24. doi: 10.1158/2326-6066.CIR-25-1081. Online ahead of print. ABSTRACT Colorectal cancer (CRC) with liver metastases (CRCLM) remains a clinical challenge. CXCL13 is widely recognized as a biomarker of immunotherapy response. However, the functional heterogeneity (protumor vs. antitumor) of CXCL13⁺CD4⁺ T cell subsets has long been controversial. Through integrated analysis of single-cell … Read more

Cancer Immunol Res. 2026 Apr 23. doi: 10.1158/2326-6066.CIR-25-0388. Online ahead of print. ABSTRACT Accumulating evidence indicates that peritoneal macrophages, comprising resident peritoneal macrophages (resMØs) and monocyte-derived non-resident macrophages (moMØs), contribute to peritoneal tumor progression, by promoting tumor cell proliferation and migration, and driving immunosuppression. However, the mechanisms governing the expansion of resMØs and moMØs, as … Read more

Cancer Immunol Res. 2026 Apr 21:OF1-OF14. doi: 10.1158/2326-6066.CIR-25-1572. Online ahead of print. ABSTRACT Colorectal cancer remains a major global health burden and an area of urgent unmet medical need. Immunotherapy has shown limited success in colorectal cancer as most patients present with an immune-excluded, “cold” tumor microenvironment (TME). In this study, we report a dual-modality … Read more

Cancer Immunol Res. 2024 Nov 4;12(11):1491. doi: 10.1158/2326-6066.CIR-12-11-WWR. NO ABSTRACT PMID:42008778 | DOI:10.1158/2326-6066.CIR-12-11-WWR

Cancer Immunol Res. 2025 May 2;13(5):617. doi: 10.1158/2326-6066.CIR-13-5-WWR. NO ABSTRACT PMID:42008760 | DOI:10.1158/2326-6066.CIR-13-5-WWR

Cancer Immunol Res. 2026 Apr 13. doi: 10.1158/2326-6066.CIR-25-0816. Online ahead of print. ABSTRACT CD8+ T cell exhaustion limits the immune response to tumors because of ineffective T cell effector functions. Thus, therapies that inhibit T-cell exhaustion are critical for optimizing cancer treatment. Recent studies have implicated epigenetic proteins in T-cell exhaustion. Here, we identified activating … Read more

Cancer Immunol Res. 2026 Apr 10. doi: 10.1158/2326-6066.CIR-25-1073. Online ahead of print. ABSTRACT Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, with low immunotherapy efficacy due to an immunosuppressive tumor microenvironment in proficient mismatch repair (pMMR) disease, which accounts for most cases of CRC. Herine, we have identified discoidin domain receptor 1 (DDR1) … Read more

Cancer Immunol Res. 2026 Apr 10. doi: 10.1158/2326-6066.CIR-25-0498. Online ahead of print. ABSTRACT Tumor-associated neutrophils (TANs) promote tumor growth and metastasis in hepatocellular carcinoma (HCC). Platelets can activate neutrophils and contribute to inflammation and organ damage; however, the relationship between TANs and platelets in HCC remains unclear. We performed multiplex immunohistochemistry and found that tumor-infiltrating … Read more